Autoimmun Diagnostika
Private Company
Total funding raised: $2.3M
Overview
Autoimmun Diagnostika (AID) is a specialized diagnostics and immunology company with over 30 years of collective experience in EliSpot technology. The company operates as an integrated provider, offering everything from assay components and kits to automated reader systems and CRO services, positioning itself as a one-stop-shop for functional cellular immunology analysis. Its focus on high-sensitivity, single-cell level detection for T and B cell responses caters to vaccine development, autoimmune disease research, and infectious disease monitoring. Based in Straßberg, Germany, AID is a private, revenue-generating entity serving the global research and clinical diagnostics community.
Technology Platform
EliSpot (Enzyme-Linked ImmunoSpot) and FluoroSpot assay platforms for the quantitative, single-cell level detection of functional T-cell and B-cell immune responses through cytokine or antibody secretion. The platform includes specialized automated reader systems for analysis.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Competes with other specialized EliSpot providers (e.g., Cellular Technology Limited, Mabtech), large diagnostic companies with broad immunoassay portfolios (e.g., Thermo Fisher, BD, Qiagen), and alternative technologies for cellular functional analysis like flow cytometry and single-cell sequencing. Differentiation is based on deep specialization, integrated systems, and over 30 years of focused expertise.